Tags

Type your tag names separated by a space and hit enter

C50 for propofol-remifentanil target-controlled infusion and bispectral index at loss of consciousness and response to painful stimulus in Chinese patients: a multicenter clinical trial.
Anesth Analg. 2009 Feb; 108(2):478-83.A&A

Abstract

BACKGROUND

In this study, we evaluated the predicted blood and effect-site C(50) for propofol and remifentanil target-controlled infusion and the Bispectral Index (BIS) values at loss of consciousness (LOC) and response to a standard noxious painful stimulus in Chinese patients. We hypothesized that these values would be different from previously published data on Caucasians.

METHODS

Five medical centers enrolled 405 ASA physical status I and II unpremedicated Chinese patients (97 men, 308 women) aged 18-65 yr. Propofol was initially given to a predicted blood concentration of 1.2 microg/mL and thereafter increased by 0.3 microg/mL every 30 s until Observer's Assessment of Alertness and Sedation score was 1. The propofol was kept constant, and remifentanil was given to provide a predict blood concentration of 2.0 ng/mL, and then increased by 0.3 ng/mL every 30 s until loss of response to a tetanic stimulus. BIS (version 3.22, BIS Quattro sensor) was also recorded.

RESULTS

The propofol effect-site C(50) at LOC was 2.2 (2.2-2.3) microg/mL. The remifentanil effect-site C(50) at loss of response to painful stimulus was 3.3 ng/mL. Fifty percent of patients lost consciousness at a BIS value of 58, and 95% had lost consciousness at BIS values <40. The BIS value at C(50) at loss of response to painful stimulus was 65.4, which was higher than that at LOS (P < 0.001).

CONCLUSIONS

The predicted blood and effect-site concentrations of propofol and BIS values at LOC were lower than those in previously published studies of Caucasian populations.

Authors+Show Affiliations

Beijing Chaoyang Hospital, Capital Medical University, Beijing, People's Republic of China.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

19151275

Citation

Xu, Zhipeng, et al. "C50 for Propofol-remifentanil Target-controlled Infusion and Bispectral Index at Loss of Consciousness and Response to Painful Stimulus in Chinese Patients: a Multicenter Clinical Trial." Anesthesia and Analgesia, vol. 108, no. 2, 2009, pp. 478-83.
Xu Z, Liu F, Yue Y, et al. C50 for propofol-remifentanil target-controlled infusion and bispectral index at loss of consciousness and response to painful stimulus in Chinese patients: a multicenter clinical trial. Anesth Analg. 2009;108(2):478-83.
Xu, Z., Liu, F., Yue, Y., Ye, T., Zhang, B., Zuo, M., Xu, M., Hao, R., Xu, Y., Yang, N., & Che, X. (2009). C50 for propofol-remifentanil target-controlled infusion and bispectral index at loss of consciousness and response to painful stimulus in Chinese patients: a multicenter clinical trial. Anesthesia and Analgesia, 108(2), 478-83. https://doi.org/10.1213/ane.0b013e31818f8a30
Xu Z, et al. C50 for Propofol-remifentanil Target-controlled Infusion and Bispectral Index at Loss of Consciousness and Response to Painful Stimulus in Chinese Patients: a Multicenter Clinical Trial. Anesth Analg. 2009;108(2):478-83. PubMed PMID: 19151275.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - C50 for propofol-remifentanil target-controlled infusion and bispectral index at loss of consciousness and response to painful stimulus in Chinese patients: a multicenter clinical trial. AU - Xu,Zhipeng, AU - Liu,Fang, AU - Yue,Yun, AU - Ye,Tiehu, AU - Zhang,Bingxi, AU - Zuo,Mingzhang, AU - Xu,Mingjun, AU - Hao,Rongrong, AU - Xu,Yuan, AU - Yang,Ning, AU - Che,Xiangming, PY - 2009/1/20/entrez PY - 2009/1/20/pubmed PY - 2009/2/10/medline SP - 478 EP - 83 JF - Anesthesia and analgesia JO - Anesth Analg VL - 108 IS - 2 N2 - BACKGROUND: In this study, we evaluated the predicted blood and effect-site C(50) for propofol and remifentanil target-controlled infusion and the Bispectral Index (BIS) values at loss of consciousness (LOC) and response to a standard noxious painful stimulus in Chinese patients. We hypothesized that these values would be different from previously published data on Caucasians. METHODS: Five medical centers enrolled 405 ASA physical status I and II unpremedicated Chinese patients (97 men, 308 women) aged 18-65 yr. Propofol was initially given to a predicted blood concentration of 1.2 microg/mL and thereafter increased by 0.3 microg/mL every 30 s until Observer's Assessment of Alertness and Sedation score was 1. The propofol was kept constant, and remifentanil was given to provide a predict blood concentration of 2.0 ng/mL, and then increased by 0.3 ng/mL every 30 s until loss of response to a tetanic stimulus. BIS (version 3.22, BIS Quattro sensor) was also recorded. RESULTS: The propofol effect-site C(50) at LOC was 2.2 (2.2-2.3) microg/mL. The remifentanil effect-site C(50) at loss of response to painful stimulus was 3.3 ng/mL. Fifty percent of patients lost consciousness at a BIS value of 58, and 95% had lost consciousness at BIS values <40. The BIS value at C(50) at loss of response to painful stimulus was 65.4, which was higher than that at LOS (P < 0.001). CONCLUSIONS: The predicted blood and effect-site concentrations of propofol and BIS values at LOC were lower than those in previously published studies of Caucasian populations. SN - 1526-7598 UR - https://www.unboundmedicine.com/medline/citation/19151275/C50_for_propofol_remifentanil_target_controlled_infusion_and_bispectral_index_at_loss_of_consciousness_and_response_to_painful_stimulus_in_Chinese_patients:_a_multicenter_clinical_trial_ L2 - https://doi.org/10.1213/ane.0b013e31818f8a30 DB - PRIME DP - Unbound Medicine ER -